Triazolyl, tetrazolyl and azido-substituted fatty acid analog enzyme substrates

ABSTRACT

Azido-substituted fatty acid analogs which are useful in the fatty acid acylation of peptides and proteins and as antiviral agents are disclosed having the following chemical structure: 
     
         Z--(CH.sub.2).sub.x COOR 
    
     wherein 
     Z=azido, tetrazolyl or triazolyl 
     R=H or C 1  -C 8  alkyl, and 
     x=8-12.

This invention was made with Government support under Grant No. AI 27179awarded by the National Institutes of Health. The Government has certianrights in the invention.

This is a continuation of application Ser. No. 07/596,183, filed Oct.12, 1990, abandoned.

BACKGROUND OF THE INVENTION

This invention relates to biologically active fatty acid analogsubstrates of myristoylating enzymes and, more particularly, toazido-substituted fatty acid analogs which are useful in the fatty acidacylation of peptides and proteins.

Fatty acid acylation of specific eukaryotic proteins is a wellestablished process which can conveniently be divided into twocategories. On the one hand, palmitate (C₁₆) is linked to membraneproteins via ester or thioester linkage post-translationally.

On the other hand, it is known that myristate (C₁₄) becomes covalentlybound to soluble and membrane proteins via amide linkage early in theprotein biosynthetic pathway. In the N-myristoylated proteins,amino-terminal glycine residues are known to be the site of acylation.

A variety of vital and cellular proteins have been shown to be thusmodified by the covalent attachment of myristate linked through an amidebound to glycine at their amino termini. An example of a most thoroughlystudied myristoylated protein is the transforming protein of Roussarcoma virus, p60^(v-src).

The myristoylation reaction can be represented as follows: ##STR1##

Further background information on the above protein fatty acid acylationcan be had by reference to the following series of articles byscientists associated with the Washington University School of Medicine:

Towler and Glaser, Biochemistry 25, 878-84 (1986);

Towler and Glaser, Proc. Natl. Acad. Sci. USA 83, 2812-2816 (1986);

Towler et al., Proc. Natl. Acad. Sci, USA 84, 2708-2712 (1987);

Towler et al., J. Biol. Chem. 262, 1030-1036 (1987);

Towler et al., Ann. Rev. Biochem. 57, 69-99 (1988);

Heuckeroth et al., Proc. Natl. Acad. Sci. USA 85, 8795-8799 (1988); and

Heuckeroth and Gordon, Proc. Natl. Acad. Sci. USA 86, 5262-5266 (1989).

Unique synthetic peptides having relatively short amino acid sequenceswhich are useful as substrates of myristoylating enzymes are describedin U.S. Pat. Nos. 4,740,588 and 4,778,878. Examples of such peptides are##STR2##

Certain other unique synthetic peptides are inhibitors of myristoylatingenzymes as described in U.S. Pat. Nos. 4,709,012 and 4,778,877.

BRIEF DESCRIPTION OF THE INVENTION

In accordance with the present invention, biologically active fatty acidanalog substrates for myristoylating enzymes are provided. Thesecompounds are azido- or azido-like-substituted fatty acid analogs whichcan also contain oxygen and/or sulfur heteroatoms in the fatty acidbackbone. They are useful in the fatty acid acylation of peptides andproteins. The preferred fatty acid analogs can be represented by thefollowing two groups of chemical structures:

    Z--(CH.sub.2).sub.x COOR                                   (I)

wherein

Z=azido, tetrazolyl or triazolyl,

R=H or C₁₋₈ alkyl, and

x=8-12.

    Compounds of structure I                                   (II)

in which a methylene group from carbon position 3 to within 2 carbons ofZ is replaced by oxygen or sulfur. The carboxyl carbon atom is definedin this structure as number 1 based on conventional nomenclature.

These novel substrate compounds are useful for studying the regulationof enzyme action in fatty acid acylation and the role ofN-myristoylation in protein function. They can serve as syntheticsubstrates for the N-myristoylating enzymes in sources such as yeasts,fungi, wheat germ lysates and mammalian cells. These novel compoundsdiffer in hydrophobicity from myristic acid while maintainingapproximately the same chain length. Thus, when incorporated intomyristoylproteins, they should alter the acylprotein's subsequentinteractions with membranes or with other proteins. They alos havepotential use as antiviral, antifungal and antineoplastic agents.

Illustrative examples of the biologically active azido-substituted fattyacid analogs of this invention are:

    ______________________________________                                        Name                   Compound No.                                           ______________________________________                                        12-Azidododecanoic acid                                                                              (1)                                                    11-Azidoundecanoic acid                                                                              (2)                                                    9-Azidononanoic acid   (3)                                                    13-Azidotridecanoic acid                                                                             (7)                                                    5-(1-Azido-hexane-6-thia)pentanoic acid                                                              (13)                                                   2-(1-Azido-nonane-9-thia)acetic acid                                                                 (19)                                                   4-(1-Azido-octane-6-thia)propionic acid                                                              (23)                                                   9-(1-Azido-ethane-2-oxa)nonanoic acid                                                                (40)                                                   8-(1-Azido-propane-3-oxa)octanoic acid                                                               (41)                                                   5-(1-Azido-hexane-6-oxa)pentanoic acid                                                               (42)                                                   2-(1-Azido-nonane-9-oxa)acetic acid                                                                  (43)                                                   12-(Tetrazolyl)dodecanoic acid                                                                       (46)                                                   12-[1,2,4]-Triazolyl)dodecanoic acid                                                                 (48)                                                   12-(N-2-[1,2,3]-Triazolyl)dodecanoic acid                                                            (50)                                                   ______________________________________                                    

DETAILED DESCRIPTION OF THE INVENTION

The azido-substituted fatty acid analogs of this invention can beprepared by various reaction schemes. For example, in one scheme anω-iodocarboxylic acid having the desired fatty acid chain length can bereacted with azide ion, e.g. potassium or sodium azide, and 18-Crown-6in organic solvent medium, e.g., DMF, at normal room temperature. Thepreparation of the reagent, 18-Crown-6, is described by Gokel et al.,Org. Syn. 57, 30 (1977).

The azido-substituted fatty acid analogs containing oxygen and/or sulfurheteroatoms in the fatty acid backbone can be synthesized by firstpreparing the oxygen and/or sulfur heteroatom-substituted fatty acidfollowed by derivatization with the azide ion. Preparation of oxa- andthia-substituted fatty acids can be carried out by methods analogous tothe preparation of mixed ethers by the Williamson synthesis under phasetransfer conditions. For example, an appropriate ω-bromo carboxylic acidor ester can be reacted with an alcohol or an alkyl thiol to produce,respectively, the oxa-substituted fatty acid ether or thethia-substituted fatty acid ether.

The preparation of the azido substituted fatty acid analogs of theinvention are preferably carried out by the following illustrativereaction Schemes: ##STR3##

The following examples will further illustrate the invention although itwill be appreciated that the invention is not limited to these specificexamples. Examples 1 to 32 illustrate the synthesis of compoundsaccording to the Reaction Schemes I to VII set forth hereinbefore.Example 33 illustrates the biological testing of representativecompounds thus synthesized in (A) an in vitro yeastN-myristoyltransferase (NMT) assay and (B) a human cell culture assay tomeasure inhibitory activity against human immunodeficiency virus (HIV).In these examples, 18-Crown-6 refers to1,4,7,10,13,16-hexaoxacyclooctadecane, THP refers to tetrahydropyran,THF refers to tetrahydrofuran, DMF refers to dimethylformamide and DMSOrefers to dimethylsulfoxide.

EXAMPLE 1

12-AZIDODODECANOIC ACID (1). A mixture of 12-iodododecanoic acid (2.1 g,0. 0064 mol), sodium azide (1.2 g, 0.019 mol) and 18-crown-6 (0.5 g,0.0019 mol) in dimethylformamide (25 ml) was stirred at room temperaturefor 16 h. After removal of the solvent under vacuum, the residue waspartitioned between 1N HCl (25 ml) and dichloromethane (25 ml). Theorganic phase was washed with water (3×25 ml), dried (Na₂ SO₄) andconcentrated to give a pale yellow liquid (3 g) which was purified byflash chromatography (silica gel) using 15% ethylacetate in hexane togive 12-azidododecanoic acid (1.3 g, 84%) as a colorless liquid. ¹ H NMR(CDCl₃) δ: 3.19 (t, 2H, J=6.9 Hz, CH₂); 2.28 (t, 2H, J=7.5 Hz, CH₂);1.53 (m, 4H, 2× CH₂); 1.21 (m, 14H), FABMS (m/z): 254 (M+2Li-H); 248(M+Li) and 226.

EXAMPLE 2

11-AZIDOUNDECANOIC ACID (2). The title compound was prepared in asimilar manner as described for 1 except that 11-iodoundecanoic acid wassubstituted for an equivalent amount of 12-iodododecanoic acid. Yield64%. ¹ H NMR (CDCl₃) δ: 3.28 (t, 2H, J=6.8 Hz, CH₂); 2.35 (t, 2H, J=7.7Hz, CH₂); 1.6 (m, 4H); 1.29 (m, 1.29 (m, 12H, --CH₂), FABMS, m/z: 228(M+H); 200 and 182.

EXAMPLE 3

9-AZIDONONANOIC ACID (3). The title compound was prepared in a similarmanner as described for 1 except that 9-iodononanoic acid wassubstituted for an equivalent amount of 12-iodododecanoic acid. Yield77%. ¹ H NMR (CDCl₃) δ:3.26 (t, 2H, J=7.00 Hz); 2.36 (t, 2H, J=5.4 Hz);1.62 (m, 4H); 1.33 (m, 8H), FABMS. m/z: 212 (M+H) and 206 (M+Li).

EXAMPLE 4

12-IODOTRIDECANOIC ACID (6). A mixture of 12-hydroxytridecanoic acid 4(0.3 g, 0.0013 mol, and iodotrimethylsilane (0.5 ml) incarbontetrachloride (3 ml) was stirred at room temperature for 16 h. Thesolution was concentrated, cold water (10 ml) was added and the mixturewas extracted with ethyl acetate (2×10 ml). The organic phase was washedwith water (2×15 ml), dried (Na₂ SO₄) and concentrated under reducedpressure. The resulting residue was purified by flash chromatography(silica gel) using 15% ethylacetate in hexane to give intermediatecompound 5 (0.2 g) as a pale yellow solid. FABMS: m/z, 565 (M+2Li-H),559 (M+Li). 5 (0.2 g) was subjected to basic hydrolysis by stirring in1N NaOH (3 ml) and THF (2 ml) at room temperature for 16 h. The solutionwas cooled, acidified with 2N HCl (1.5 ml) and extracted withethylacetate (2×10 ml). The organic phase was washed with water (2×10ml), dried (Na₂ SO₄), concentrated under reduced pressure and theresidue was purified by flash chromatography (silical gel) using 10%ethylacetate in hexane to give the title compound 6 (0.15 g, 34%). ¹ HNMR (CDCl₃) δ: 3.19 (t, 2H, J=6.9 Hz); 2.35 (t, 2H, J=7.5 Hz); 1.85 (m,2H); 1.64 (m, 2H), 1.27 (m, 16H); FABMS: m/z, 353 (M+2Li-H); 347 (M+Li)and 225. HRMS: M/Z, C₁₃ H₂₅ IO₂ Li, calc.: 275.2059; found: 275.2004(M+Li).

EXAMPLE 5

13-AZIDOTRIDECANOIC ACID (7). A mixture of 6 (0.15 g, 0.44 mmol) sodiumazide (0.09 g, 1.4 mmol) and 18-crown-6 (0.015 g, 0.057 mmol) indimethylformamide (3 ml) was stirred at room temperature for 16 h. DMFwas distilled under vacuum, cold 2N HCl (2 ml) was added and the mixturewas extracted with ethylacetate (10 ml). The organic phase was washedwith water (2×10 ml), dried (Na₂ SO₄) and concentrated under reducedpressure to give a pale yellow solid which was purified by flashchromatography (silica gel) using 20% ethylacetate in hexane to affordthe title compound 7 (0,075 g, 67%) as a white solid. ¹ H NMR (CDCl₃) δ:3.26 (t, 2H, J=6.9 Hz); 2.35 (t, 2H, J=7.5 Hz); 1.62 (m, 4H); 1.35 (m,14H), FABMS: (m/z), 256 (M+H); 230 and 210. HRMS C₁₃ H₂₅ N₃ O₂ Li calc.:262.2107, found: 262.2164 (M+Li).

EXAMPLE 6

1-(TETRAHYDROPYRANLOXY) -6-THIOACETYL HEXANE (9 ). To a solution ofpotassium thioacetate (0.34 g, 0.003 mol) and 18-crown-6 (0.16 g, 0.0006mol) in DMF (5 ml), was added a solution of THP--O--(CH₂)₆ I 8 (0.7 g,0.0022 mol) in DMF (2 ml). The reaction mixture was stirred at roomtemperature for 2 h, DMF was distilled under vacuum and the residue waspartitioned between water (25 ml) and dichloromethane (25 ml). Theorganic phase was washed with water (2×10 ml), dried (Na₂ SO₄) andconcentrated. The resulting material was purified by flashchromatography (silica gel) using 10% ethylacetate in hexane to give thetitle compound 9 (0.5 g, 86%) as a colorless liquid. ¹ H NMR (CDCl₃) δ:4.57 (m, 1H); 3.75 (m, 2H), 3.45 (m, 2H); 2.87 (t, 2H); 2.32 (s, 3H,--COCH₃); 1.75 (m, 2H); 1.6 (m, 8H); 1.39 (m, 4H), FABMS: m/z, 267(M+Li) and 183.

EXAMPLE 7

t-BUTYL-5-(1-TETTRAHYDROPYRANYLOXY-HEXANE-6-THIA) PENTANOATE(10). Amixture of 9(0.45 g, 0.0017 mol), t-butyl-5-bromovalerate (0.49 g, 0.002mol) and tetrabutylammonium hydrogen sulphate (0.25 g, 0.70 mol) wasstirred vigorously in 50% sodium hydroxide (0.8 ml), toluene (2.0 ml)and THF (2.0 ml) at room temperature for 3 h and at 60° C. for 1 h. Thereaction mixture was poured into ice and diluted with water (10 ml). Theorganic phase was washed with water (3×15 ml), dried (Na₂ SO₄) andconcentrated to give a thick syrup, which was purified by flashchromatography (silica gel) using 10% ethyl acetate in hexane to affordthe title compound 10 (0.65 g, 90%) as a colorless oil. ¹ H NMR (CDCl₃)δ: 4.57 (m, 1H); 3.8 (m, 2H); 3.45 (m, 2H); 2.51 (m, 2H); 2.23 (t, 2H);1.6 (m, 12H), 1.44 (s, 9H); 1.4 (m, 8H), FABMS: m/z, 381 (M+Li); 325,241 and 217.

EXAMPLE 8

t-BUTYL-5-(1-HYDROXY HEXYL-6-THIA)PENTANOATE (11). A solution of 10(0.65 g, 0.0017 mol) in methanol (5 ml), containing p-toluenesulfonicacid (0.1 g, 0.53 mmol) was stirred at room temperature for 2 h. To thissolution was added sodium bicarbonate (0.15 g) and the mixture wasconcentrated under reduced pressure. The residue was purified by flashchromatography (silica gel) using 15% ethylacetate in hexane to give thetitle compound 11 (0.36 g, 71%) as a colorless syrup. ¹ H NMR (CDCl₃) δ:3.65 (q, 2H); 2.51 (t, 4H); 2.23 (t, 2H); 1.6 (m, 8H); 1.44 (s, 9H);1.40(m, 4H); 1.25 (t, 1H, --OH), FABMS: m/z, 297(M+Li); 241 and 195.

EXAMPLE 9

t-BUTYL-5-(1-IODO-HEXANE-6-THIA) PENTANOATE (12). A mixture of 11 (0.35g, 0.0012 mol) and methyltriphenoxyphosphonium iodide (0.7 g, 0. 0015mol) in acetonitrile (5 ml) was stirred at room temperature for 2.5 h.After removal of the solvent, the residue was dissolved indichloromethane (25 ml) and a cold solution of 0.5N NaOH was added. Theorganic phase was washed with water (3×15 ml), dried (Na₂ SO₄),concentrated under reduced pressure and the residue was purified byflash chromatography using 3% ethylacetate in hexane to yield the titlecompound 12 (0.49, 83%) as a colorless liquid. ¹ H NMR (CDCl₃) δ: 3.39(m, 4H); 3.19 (t, 2H); 2.34 (t, 2H); 1.75 (m, 2H); 1.6 (m, 6H); 1.44 (s,9H); 1.39 (m, 4H), FABMS: m/z, 407 (M+Li); 401 (M+H); 345, 327 and 217.

EXAMPLE 10

5-(1-AZIDO-HEXANE-6-THIA) PENTANOIC ACID (13). A mixture of 12 (0.36 g,0.9 mmol) and iodotrimethylsilane (0.2 ml) in carbontetrachloride (3.0ml) was stirred at room temperature for 4 h. The solution was cooled,cold water (10 ml) was added and the mixture extracted withcarbontetrachloride (2×5 ml). The organic phase was successively washedwith 5% sodium sulphite (5 ml), water (3×10 ml) and dried (Na₂ SO₄). Thesolution was concentrated under reduced pressure and dried under vacuumto give 0.16 g of a thick syrup. This product was dissolved indimethylformamide (2 ml), to which was added sodium azide (0.096 g,0.0015 mol) and 18-crown-6 (0.01 g) and then stirred at room temperaturefor 16 h. The solvent was distilled under vacuum, 1N HCl (10 ml) wasadded and the mixture was extracted with ethylacetate (2×10 ml). Theorganic phase was washed with water (2×10 ml), dried (Na₂ SO₄),concentrated and the residue was purified by flash chromatography(silica gel) using 15% ethylacetate in hexane to afford the titlecompound 13 (0.07 g, 58%) as a colorless liquid. ¹ H NMR (CDCl₃) δ: 3.27(t, 2H); 2.51 (m, 4H); 2.39 (t, 2H); 1.7 (m, 8H); 1.4 (m, 4H), FABMS:m/z, 272 (M+2Li-H); 266 (M+Li) and 244. HRMS: m/z, C₁₁ H₂₁ N₃ SO₂ Li,calc: 266.1516, found: 266.1491 (M+Li).

EXAMPLE 11

METHYL L-2-(1-TETRAHYROPYRANYLOXY-NONANE-9-THIA)ACETATE (15). To asolution of THP--O--(CH₂)₉ I 14 (0.23 g, 0.65 mmol) and methylthioglycolate (0.1 g, 0.94 mmol) in acetonitrile, was addedtriethylamine (0.17 ml, 1.2 mmol) was added and the mixture was stirredat room temperature for 2 h. The solution was concentrated, water (10ml) was added and the mixture was extracted with ethylacetate (2×10 ml).The organic phase was washed with water (2×10 ml), dried (Na₂ SO₄),concentrated under reduced pressure and the residue was purified byflash chromatography (silica gel) using 5% ethylacetate in hexane togive the title compound 15 (0.2 g, 92%) as a colorless oil. ¹ H NMR(CDCl₃) δ: 4.57 (m, 1H); 3.85 (m, 1H), 3.74 (s, 3H); 3.71 (m, 1H); 3.5(m, 1H); 3.4 (m, 1H); 3.2 (s, 2H, --OCH₂), 2.62 (t, 2H); 1.75 (m, 2H);1.57 (m, 8H); 1.3 (m, 1OH). FABMS; m/z, 339 (M+Li); 249 and 231.

EXAMPLE 12

METHYL-2-(1-HYDROXYNONANE-9-THIA)ACETATE (16). The tetrahydropyranylgroup in 15 (0.2 g, 0.6 mmol) was cleaved using p-toluenesulfonic acidin a similar manner as described for cleavage of the THP group in 10 inExample 8 to provide the title compound 16 Yield 0.14 g (93%). ¹ H NMR(CDCl₃) δ: 3.74 (s, 3H, OCH₃); 3.65 (q, 2H); 3.23 (s, 2H, --OCH₂); 2.63(t, 2H); 1.6 (m, 4H); 1.3 (m, 10H); 0.9 (t, 1H). FABMS: m/z, 255 (M+Li).

EXAMPLE 13

METHYL-2-(1-IODO-NONANE-9-THIA)ACETATE (17). The title compound 17 wasprepared by the iodination of 16 (0.27 g, 1.1 mmol) usingmethyltriphenoxyphosphonium iodide in a manner similar to that describedfor the preparation of 12 in Example 9. Yield 0.24 g, 62%. ¹ H NMR(CDCl₃) δ: 3.74 (s, 3H, OCH₃); 3.23 (s, 2H, --OCH₂); 3.19 (t, 2H); 2.63(t, 2H); 1.82 (m, 2H); 1.60 (m, 2H); 1.33 (m, 10H). FABMS: m/z, 365(M+Li), 359 (M+H) and 237.

EXAMPLE 14

METHYL-2-(1-AZIDONONANE-9-THIA)ACETATE (18). A mixture of 17 (1.5 g, 4.2mmol), sodium azide (0.5 g, 7.7 mmol) and 18-crown-6 (0.12 g, 0.45 mmol)in dimethylformamide (5 ml) was stirred at room temperature for 16 h.The solution was concentrated under high vacuum and the residue waspartitioned between water (10 ml) and dichloromethane (15 ml). Theorganic phase was washed with water (3×10 ml), dried (Na₂ SO₄),concentrated and the residue was purified by flash chromatography using5% ethylacetate in hexane to furnish the title compound 18 (1.04 g, 83%)as a colorless liquid. ¹ H NMR (CDCl₃) δ: 3.74 (s, 3H, OCH₃); 3.26 (t,2H); 3.23 (s, 2H, OCH₂); 2.63 (t, 2H), 1.59 (m, 4H); 1.31 (m, 10H).FABMS: m/z, 280 (M+Li) and 252.

EXAMPLE 15

2-(1-AZIDONONANE-9-THIA)ACETIC ACID (19). A solution of 18 (0.54 g, 2mmol) in 1N methanolic sodium hydroxide (8 ml) and THF (2 ml) wasstirred at room temperature for 4 h. The reaction mixture wasconcentrated to dryness, water (10 ml) was added, and the mixture wasneutralized with 2N HCl (4 ml) and extracted with dichloromethane (2×10ml). The organic layer was washed with water (2×10 ml), dried (Na₂ SO₄),concentrated and the residue was purified by flash chromatography using25% ethylacetate in hexane to afford the title compound 19 (0.4 g, 78%)as a colorless liquid. ¹ H NMR (CDCl₃) δ: 3.28 (t, 2H); 3.28 (s, 2H,--OCH₂); 69 (t, 2H); 1.63 (m, 4H); 1.38 (m, 10H) ¹³ C NMR (CDCl₃) δ:26.62, 28.59, 28.77, 28.81, 28.97, 29.24, 32.74, 33.47, 51.42 and176.95. FABMS: (m/z), 272 (M+2Li-H); 266 (M+Li); 244 and 238. HRMS: m/z,C₁₁ H₂₁ N₃ O₂ Li, calc: 266.1516, found: 266.1502 (M+Li).

EXAMPLE 16

4-(1-IODOOCTANE-8-THIA)PROPIONIC ACID (22). A mixture of diiodooctane 20(2.8 g, 7.65 mmol), 3-mercaptopropionic acid 21 (0.75 ml, 8.6 mmol),dimethylaminopyridine (0.1 g, 0.82 mmol) and triethylamine (2.4 ml, 17.1mmol) in acetonitrile (20 ml) was stirred at room temperature for 16 h.After removal of the solvent under reduced pressure, the residue waspartitioned between 1N HC1 (25 ml) and dichloromethane (25 ml). Theorganic phase was washed with water (3×15 ml), dried (Na₂ SO₄),concentrated under reduced pressure and the residue was purified byflash chromatography (silica gel) using 20% ethylacetate in hexane togive the title compound 22 (0.3 g, 11%) as a low melting solid. ¹ H NMR(CDCl₃) δ: 3.19 (t, 2H, 6.9 Hz); 2.78 (m, 2H); 2.66 (m, 2H); 2.54 (m,2H); 1.82 (m, 2H); 1.6 (m, 2H); 1.33 (m, 8H). FABMS: m/z, 357 (m+2Li-H);351 (M+Li); 223 (M+Li-HI). HRMS: m/z, C₁₁ H₂₁ IO₂ SLi, calc: 351.0467,found: 351.0484 (M+Li).

EXAMPLE 17

4-(1-AZIDOOCTANE-6-THIA)PROPIONIC ACID (23). The title compound 23 wasobtained by stirring a solution of 22 in DMF containing sodium azide and18-crown-6 in a similar manner as described for the preparation ofcompound 1 in Example 1. Yield 66%. ¹ H NMR (CDCl₃) δ: 3.26 (t, 2H);2.77 (t, 2H); 2.67 (t, 2H); 2.54 (t, 2H); 1.59 (m, 4H); 1.33 (m, 8H).13C NMR (CDCl₃) δ: 26.58; 26.60; 28.66; 28.77; 28.97; 28.99; 29.41;32.13; 34.69; 51.42, 178.15. FABMS: m/z, 272 (M+Li-H); 266 (M+Li); 244and 229. HRMS: m/z, C₁₁ H₂₁ N₃ O₂ SLi, calc: 266.1516, found: 266.1510(M+Li).

EXAMPLE 18

t-BUTYL-9-(1-TETRAHYDROPYRANYLOXY-ETHANE-2-OXA) NONANOATE (32). Amixture of 24 (0.97 g, 0.0066 mol) and 28 (1.2 g, 0.004 mol) in 50%aqueous NaOH (2.7 ml) and toluene (3.0 ml) containingtetrabutylammoniumhydrogen sulfate (0.25 g, 0.74 mmol) was stirred atroom temperature for 16 h. The reaction mixture was poured into coldwater (15 ml) and extracted with ethylacetate (3×15 ml). The organicphase was washed with water (3×15 ml), dried (Na₂ SO₄) and concentratedunder reduced pressure to give 1.5 g of liquid which was purified(twice) by flash chromatography (silica gel) using 10% EtOAc in hexanecontaining 0.2% Et₃ N to give 0.73 g (50%) of the title compound 32 as acolorless liquid. ¹ H NMR (CDCl₃) δ: 4.64 (m, 1H); 3.85 (m, 2H); 3.60and 3.47 (m, 6H); 2.19 (t, 2H, J=7.2 Hz); 1.8 (m, 2H); 1.56 (m, 8H);1.44 (s, 9H); 1.29 (bs, 8H). FABMS: m/z, 365 (M+Li), 309, 225 and 201.

EXAMPLE 19

t-BUTYL-8-(1-TETRAHYDROPYRANYLOXY-PROPANE-3-OXA)-OCTANOATE (33). Thetitle compound 33 was prepared from 25 and 29 in a manner similar to thepreparation of 32 in Example 18. Yield 41%. ¹ H NMR (CDCl₃) δ: 4.58 (m,1H); 3.83 (m, 2H); 3.52, 3.40 (2m, 6H); 2.22 (t, 2H); 1.86 (m, 2H); 1.55(m, 10H); 1.44 (s, 9H); 1.31 (m, 6H). FABMS: m/z=365 (M+Li), 309 and275. HRMS: m/z, C₂₀ H₃₈ O₅ Li, calc: 365.2879, found: 365.2870 (M+Li).

EXAMPLE 20

t-BUTYL-5-(1-TETRAHYDROPYRANYLOXY-HEXANE-6-OXA-PENTANOATE (34). To anice-cold solution of 26 (0.7 g, 0.0035 mol) and t-butyl-5-bromovalerate30 (0.6 g, 0.0029 mol) in toluene (2 mL), 50% aq. NaOH solution (1.4 mL)and tetrabutylammonium hydrogen sulfate (0.12 g, 0.35 mmol) were added.The resulting mixture was stirred for 30 min. at 0° C. and then for 4 hat room temperature. The reaction was poured into 10 mL of ice-water andextracted with EtOAc (2×15 mL). The organic phase was washed with water(3×15 mL), dried (Na₂ SO₄) and concentrated in vacuo to afford a pale,yellow liquid (1.1 g) which was purified by flash chromatography using20% EtOAc in hexane containing 0.2% Et₃ N as the eluent. The unreactedbromovalerate 30 (0.31 g, 46%) eluted first, followed by the titlecompound 34. The chromatography fractions containing 12 were combined,concentrated, and dried under high vacuum to afford 0.34 g of 34 (32%)as a colorless oil. R_(f) 0.63 (50% EtOAc in hexane). ¹ H NMR, 4.56 (t,1H); 3.87 (m, 1H); 3.75 (m, 1H); 3.39 (m, 6H); 2.24 (t, 2H), 1.3-1.9 (m,27H). FABMS: m/z 376 (M+NH₄). HRMS: m/z, C₂₀ H₃₈ O₅ Li, calc: 365.2879,found: 365.2901.

EXAMPLE 21

t-BUTYL-2-(1-TETRAHYDROPYRANYLOXY-NONANE-9-OXA)ACETATE (35). The titlecompound was prepared in a manner similar to the preparation of compound32 in Example 18. Yield 64%.

¹ H NMR (CDCl₃) δ: 4.58 (m, 1H); 3.9 (s, 2H); 3.85 and 3.75 (m, 2H); 3.5(t, 2H); 3.39 (m, 2H); 1.58 (m, 10H); 1.48 (s, 9H); 1.31 (m, 10H).FABMS: m/z=365 (M+Li), 309 and 225.

EXAMPLE 22

t-BUTYL-9-(1-IODO-ETHANE-2-OXA)NONANOATE (36). A solution of 32 (0.7 g,2.0 mmol) in methanol (3 ml) containing p-toluenesulfonic acid (0.1 g,0.53 mmol) was stirred at room temperature for 1 h, NaHCO₃ (0.1 g) wasadded and the mixture was concentrated. The residue was purified byflash chromatography (silica gel) using 25% EtOAc in hexane to give 0.52g of a colorless liquid. This product was dissolved in acetonitrile (7ml), methyltriphenoxy phosphonium iodide (1.15 g, 2.5 mmol) was addedand the mixture was stirred at room temperature for 4 h. The reactionmixture was concentrated to dryness, water (15 ml) was added and themixture was extracted with ethylacetate (3×15 ml). the organic phase waswashed with 5% sodium thiosulphate (10 ml) water (3×15 ml), dried (Na₂SO₄) and concentrated. The residue was purified by flash chromatography(silica gel) using 4% ethylacetate in hexane to give the title compound36 (0.46 g, 66%) as a colorless liquid.

¹ H NMR (CDCl₃) δ: 3.68 (t, 2H); 3.47 (t, 2H); 3.25 (t, 2H); 2.2 (t,2H); 1.55 (m, 4H); 1.44 (s, 9H); 1.31 (m, 8H). FABMS: m/z=391 (M+Li),335, 329 and 253. HRMS: m/z, C₁₅ H₂₉ IO₃ Li, calc. 391.1322, found391.1364 (M+Li).

EXAMPLE 23

t-BUTYL-8-(1-IODO-PROPANE-3-OXA)OCTANOATE (37). The title compound 37was prepared from 33 in a manner similar to the preparation of compound36 in Example 22. Yield 65%. ¹ H NMR (CDCl₃) δ: 3.44 (m, 4H); 3.28 (t,2H J=6.9 Hz); 2.2 (t, 2H, J=7.5 Hz); 2.05 (m, 2H); 1.58 (m, 4H); 1.44(s, 9H); 1.32 (m, 6H), FABMS: m/z, 391(M+Li), 335. HRMS: m/z, C₁₅ H₂₉IO₃ Li, calc: 391.1322, found: 391.1353 (M+Li).

EXAMPLE 24

t-BUTYL-5-(1-IODO-HEXANE-6-OXA)PENTANOATE (38 ). The title compound 38was prepared from 34 in a manner similar to the preparation of compound36 in Example 22. Yield 77%. ¹ H NMR (CDCl₃) δ: 3.39 (m, 4H); 3.19 (t,2H, J=6.9 Hz); 2.24 (t, 2H); 1.85 (m, 2H); 1.6 (m, 6H); 1.49 (s, 9H);1.39 (m, 4H). FABMS: m/z 391 (M+Li); 335 and 211. HRMS: m/z, C₁₅ H₂₉ IO₃Li, calc: 391.1322, found: 391.1374 (M+Li).

EXAMPLE 25

t-BUTYL-2-(1-IODO-NONANE-9-OXA)ACETATE (39). The title compound 39 wasprepared from 35 in a manner similar to the preparation of 36 in Example22. Yield 69%. ¹ H NMR (CDCl₃) δ: 3.95 (s, 2H); 3.5 (t, 2H); 3.19 (t,2H); 1.8 (m, 2H); 1.6 (m, 2H), 1.48 (s, 9H); 1.3 (m, 10H). FABMS: m/z,391 (M+Li); 335, 329, 283 and 253.

EXAMPLE 26

9-(1-AZIDO-ETHANE-2-OXA)NONANOATE (40). A solution of 36 (0.45 g, 1.2mmol) and iodotrimethylsilane (0.25 ml) in carbontetrachloride (3 mol)was stirred at room temperature for 1.5 h. The solution was concentratedunder reduced pressure, 0.5N HCl (5 ml) and dichloromethane (15 ml) wereadded. The organic phase was washed with water (3×10 ml), dried (Na₂SO₄), concentrated and the residue was dried in vacuo to give 0.36 g.This product was dissolved in DMF (5 ml), sodium azide (0.24 g, 3.7mmol) and 18-Crown-6 (0.025, 0,095 mmol) were added and the mixture wasstirred at room temperature for 6 h. The solution was concentrated, 0.5NHCl (5 ml) was added and the mixture was extracted with ethylacetate(2×10 ml). The organic phase was washed with water (2×15 ml), dried (Na₂SO₄), concentrated under reduced pressure, and the residue was purifiedby flash chromatography (silica gel) using 20% EtOAc in hexane to givethe title compound 40 (0.19 g, 64%) as a colorless liquid. ¹ H NMR(CDCl₃) δ: 3.6 (t, 2H), 3.47 (t, 2H); 3.38 (t, 2H); 2.35 (t, 2H, J=7.5Hz); 1.61 (m, 4H); 1.32 (m, 8H); ¹³ C NMR (CDCl₃) δ: 24.60, 25.86,28.91, 29.09, 29.13, 29.53, 34.02, 50.72, 69.44, 71.39, 180.09. FABMS:m/z=261 (M+NH₄ ); 244 (M+H). HRMS: m/z=C₁₁ H₂₁ N₃ O₃ Li, calc: 250.1743,found: 250.1731 (M+Li ).

EXAMPLE 27

8-(1-AZIDO-PROPANE-3-OXA)OCTANOIC ACID (41). The title compound 41 wasprepared in a similar manner as compound 40 in Example 26 except thatreactant compound 37 was substituted for an equivalent amount of 36.Yield 65%. ¹ H NMR (CDCl₃) δ: 3.48 (t, 2H, J=6.0 Hz); 3.41 (m, 4H); 2.35(t, 2H, J=7.5 Hz); 1.84 (m, 2H); 1.6 (m, 4H); 1.34 (m, 6H). ¹³ C NMR(CDCl₃) δ: 24.42, 25.76, 28.59, 29.05, 29.37, 33.81, 33.86, 48.36,67.11, 70.92, 179.88. FABMS: m/z=261 (M +NH₄ ⁺); 244 (M+H) and 216.HRMS: m/z=C₁₁ H₂₁ N₃ O₃ Li, calc: 250.1743, found: 250.1702 (M+Li ).

EXAMPLE 28

5-(1-AZIDO-HEXANE-6-OXA)PENTANOIC ACID (42). The title compound 42 wasprepared in a similar manner as compound 40 in Example 26 except thatreactant compound 38 was substituted for an equivalent amount of 36.Yield 73%. ¹ H NMR (CDCl₃) δ: 3.4 (m, 4H), 3.29 (t, 2H, J=6.9 Hz); 2.4(t, 2H, J=7.2 Hz); 1.65 (m, 8H); 1.39 (m, 4H). FABMS: m/z: 261 (M+NH₄⁺); 244 (M+H) and 216. HRMS: m/z=C₁₁ H₂₁ N₃ O₃ Li, calc: 250.1743,found: 250.1779 (M+Li).

EXAMPLE 29

2-(1-AZIDO-NONANE-9-OXA)ACETIC ACID (43). The title compound 43 wasprepared in a similar manner as compound 40 in Example 26 except thatreactant compound 39 was substituted for an equivalent amount of 36-Yield 50%. ¹ H NMR (CDCl₃) δ: 4.09 (s, 2H, OCH₂); 3.58 (t, 2H, J=6.6Hz); 3.26 (t, 2H, J=7.2 Hz); 1.61 (m, 4H); 1.32 (m, 10H). FABMS: m/z=250(M+Li) and 228. HRMS: m/z=C₁₁ H₂₁ N₃ O₃ Li, calc: 250.1743, found:250.1741 (M+Li).

EXAMPLE 30

12-(TETRAZOLYL)DODECANOIC ACID (46). A suspension of NaH (0.045 g, 80%suspension in oil) in DMF (1 ml) was added to a solution of tetrazole 44(0.095 g, 1.35 mmmol) in DMF (1 ml). After stirring the reactants for 15min, a solution of 12-iodo-dodecanoic acid 45 (0.2 g, 0.6 mmol) wasadded. The resulting mixture was stirred at room temperature for 1 h andat 55° C. for 1.5 h and then concentrated in vacuo. The residue wastreated with 1N HCl(5 ml) and extracted with EtOAc (2×10 ml). Theorganic layer was washed with water, dried (Na₂ SO₄), concentrated underreduced pressure and the residue was crystallized from EtOAc/Hexane togive the title compound 46 (0,095 g, 26%) as a 1:3 mixture of N-3 andN-1 isomers, respectively. This mixture was tested directly as asubstrate for NMT. ¹ H NMR (CDCl₃) δ: 8.59 and 8.5 (2s, 1H); 4.65 and4.43 (2t, 2H, J=7.2 Hz); 2.35 (t, 2H, J=7.5 Hz); 1.95 (m, 2H); 1.63 (m,2H); 1.26 (m, 14H). FABMS: m/z 269 (M+H); 251 and 241. HRMS: m/z=C₁₃ H₂₄N₄ O₂ Li, calc: 275.2059, found: 275.2004 (M+Li).

EXAMPLE 31

12-[1,2,4]TRIAZOLYCDODECANOIC ACID (48). To a suspension of sodiumhydride (0.05 g, of 80% suspension in oil) in DMF cooled to 0° C., wasadded dropwise a solution of 1,2,4-triazole 47 (0.095 g, 1.38 mmol) inDMF (1.5 ml). The reaction mixture was stirred at 0° C. for 30 min., asolution of 12-iodododecanoic acid 45 (0.2 g, 0.6 mmol) and 18-crown-6(0.01 g, 0.038 mmol) in DMF (1 ml), was added, and stirred at roomtemperature for 1 h and at 60° C. for 1.5 h. DMF was distilled underreduced pressure, the residue was dissolved in water (5 ml), acidifiedwith 1N HCl to pH6 and extracted with ethyl acetate (2×15 ml). Theorganic phase was washed with water (2×10 ml), dried (Na₂ SO₄) andconcentrated under reduced pressure. The residue was purified bycrystallization from ethyl acetate hexane (1:1) to give 48 (0.055 g,34%) as a white powder. ¹ H NMR (CDCl₃) δ: 8.10 (s, 1H), 7.96 (s, 1H),4.17 (t, 2H, J=7.2 Hz), 2.35 (t, 2H, J=7.5 Hz); 1.88 (m, 2H), 1.63 (m,2H), 1.26 (m, 14H). FABMS: m/z=268 (M+H).

EXAMPLE 32

12-(N-2-[1,2,3]TRIAZOLYL)DODECANOIC ACID (50). To a suspension of sodiumhydride (0.13 g, ef 80% suspension in oil) in DMF (4 ml) cooled to 0°C., was added dropwise a solution of 1,2,3-triazole 49 (0.28 g, 0. 004mmol) in DMF (1 ml). After 0.5 h, 18-crown-6 (0.025 g, 0.095 mmol) and12-iodododecanoic acid 45 (0.5 g, 0.0016 mol) were added and the mixturewas stirred for 1 h at room temperature and 1.5 h at 60° C. undernitrogen atmosphere. The reaction mixture was concentrated under vacuum,the residue was dissolved in water (10 ml), acidified with cold 1N HCland the resulting mixture was extracted with ethyl acetate (3×15 ml).The organic phase was washed with water (2×10 ml), dried (Na₂ SO₄),concentrated under reduced pressure and the residue was crystallizedfrom ethyl acetate to afford the title compound 50 (0.12 g, 28%) as awhite crystalline substance. m.p. 79°-80° C.; ¹ H NMR (CDCl₃) δ: 7.59(s, 2H), 4.44 (t, 2H, J=7.2 Hz); 2.35 (t, 2H, J=7.2 Hz), 1.95 (m, 2H);1.63 (m, 2H), 1.26 (m, 14H). FABMS: m/z=274 (M+Li). HRMS: m/z=C₁₄ H₂₅ N₃O₂ Li, calc: 274.2107, found: 274.2105.

EXAMPLE 33

A. Representative compounds prepared in the foregoing illustrativespecific examples were analyzed in a conventional in vitro yeastN-myristoyltransferase (NMT) assay as published by Heuckeroth et al.,Proc. Nat'l Acad. Sci. USA 85, 8795-8799 (1988). In this assay, the testcompounds were first converted to their respective fatty acyl CoAderivatives and then tested as substrates for the yeast NMT.

The assay conditions [essentially the same as those reported by Towlerand Glaser, Proc. Natl. Acad. Sci. USA 83, 2812-2816 (1986)] were asfollows:

1. Ligase reaction: 3.3 μmoles fatty acid, 5 mM ATP and 1 mM CoA wereincubated with 15-150 milliunits of CoA ligase (1 unit/ml in 50 mMHEPES, pH 7.3) in a buffer composed of 10 mM TRIS-HCl, pH 7.4, 1 mMdithiothreitol, 5 mM MgCl₂ and 0.1 mM EGTA, in a total volume of 50 μlfor 25 minutes at 30° C.

2. NMT assay: 50 μl of the CoA ligase mixture was added to a 50 μlsolution of 90 μM peptide (GSAASARR-NH₂) in a buffer composed of 10 mMTRIS-HCl, pH 7.4, 1 mM dithiothreitol, 0.01 mM EGTA and aprotinin (10μg/ml). 0.4 Unit of yeast N-myristoyltransferase was then added and thereaction mixture was incubated at 30° C. for 10 minutes. The peptide wasradiolabeled with tritiated alanine in position 3. The reaction wasquenched with 120 μl of TCA-MeOH and 75 μl was injected on a reversephase C18 HPLC column and eluted with a linear gradient of 0-100%acetonitrile over 100 minutes (both water and acetonitrile containing0.1% trifluoroacetic acid). Radioactivity was assessed with an on lineradiomatic detector corrected for quenching.

The amount of radioactivity was determined for each azido-substitutedfatty acyl peptide product and then was normalized to the amount ofmyristoyl peptide produced in an assay run in parallel.

The activity of each fatty acid analog was thus expressed as apercentage of the activity exhibited by unsubstituted myristate(control) and recorded in the following Table 1.

                  TABLE 1                                                         ______________________________________                                        Substrate Activity of Azido-Substituted Fatty Acid Analogs                    Synthesis                                                                     Example                                                                       Test    Myristate Analog      Activity (%                                     Compound                                                                              Test Compound         of Myristate)                                   ______________________________________                                        Example 1                                                                             N.sub.3 (CH.sub.2).sub.11 COOH (1)                                                                  142                                             Example 2                                                                             N.sub.3 (CH.sub.2).sub.10 COOH (2)                                                                  100                                             Example 3                                                                             N.sub.3 (CH.sub.2).sub.8 COOH (3)                                                                   55                                              Example 26                                                                            N.sub.3 (CH.sub.2).sub.2 --O--(CH.sub.2).sub.8 COOH                                                 280)                                            Example 27                                                                            N.sub.3 (CH.sub.2).sub.3 --O--(CH.sub.2).sub.7 COOH                                                 421)                                            Example 28                                                                            N.sub.3 (CH.sub.2).sub.6 --O--(CH.sub.2).sub.4 COOH                                                 622)                                            Example 29                                                                            N.sub.3 (CH.sub.2).sub.9 --O--CH.sub.2 COOH (43)                                                    11                                              Example 10                                                                            N.sub.3 (CH.sub.2).sub.6 --S--(CH.sub.2).sub.4 COOH                                                 103                                             Example 13                                                                            N.sub.3 (CH.sub.2).sub.9 --S--CH.sub.2 COOH (19)                                                    17                                              Example 23                                                                            N.sub.3 (CH.sub.2).sub.8 --S--(CH.sub.2).sub.2 COOH                                                 373)                                            Example 30                                                                            Tetrazolyl-(CH.sub.2).sub.11 COOH (46)                                                              46                                              Example 31                                                                            1,2,4-Triazoyl-(CH.sub.2).sub.11 COOH (48)                                                          23                                              Example 32                                                                            1,2,3-Triazoyl-(CH.sub.2).sub.11 --COOH (50)                                                        99                                              ______________________________________                                    

B. Representative compounds prepared in the foregoing illustrativespecific examples were also tested in vitro for the assessment ofanti-viral (HIV) activity as follows:

ASSAY INFORMATION

The HIV inhibition assay method of acutely infected cells is anautomated tetrazolium based colorimetric assay adatped from thatreported by Pauwles et al., J. Virol. Methods, 20, 309-321 (1988).Assays were performed in 96-well tissue culture plates. CEM cells weregrown in RPMI-1640 medium (Gibco) supplemented with 10% fetal calf serumand were then treated with polybrene (2 μg/ml). An 80 μl volume ofmedium containing 1×10⁴ cells was dispensed into each well of the tissueculture plate. To each well was added a 100 μl volume of test compounddissolved in tissue culture medium (or medium without test compound as acontrol) to achieve the desired final concentration and the cells wereincubated at 37° C. for 1 hour. A frozen culture of HIV-1 was diluted inculture medium to a concentration of 5×10⁴ TCID₅₀ per ml (TCID₅₀ =thedose of virus that infects 50% of cells in tissue culture), and a 20 μlvolume of the virus sample (containing 1000 TCID₅₀ of virus) was addedto wells containing test compound and to wells containing only medium(infected control cells). This results in a multiplicity of infection of0.1 (MOI=# of infectious virus particles/# of cells in culture). Severalwells received culture medium without virus (uninfected control cells).Likewise, the intrinsic toxicity of the test compound was determined byadding medium without virus to several wells containing test compound.In summary, the tissue culture plates contained the following tests (intriplicate):

    ______________________________________                                        cells       drug   virus                                                      ______________________________________                                        1.    +         -      -       uninfected cell control                        2.    +         +      -       uninfected drug control                        3.    +         -      +       infected cell control                          4.    +         +      +       test case                                      ______________________________________                                    

In tests 2 and 4 the final concentrations of test compounds were 1, 10,100 and 500 μg/ml. Azidothymidine (AZT) was tested as a positive drugcontrol, and dodecanoic acid was tested as a negative fatty acidcontrol. Test compounds were dissolved in DMSO and diluted into tissueculture medium so that the final DMSO concentration did not exceed 1.5%in any case. Under these conditions, DMSO had no significant effect onresults as determined in controls.

Following the addition of virus, cells were incubated at 37° C. in ahumidified, 5% CO₂ atmosphere for 7 days. Additional aliquots of testcompounds were added on days 2 and 5. On day 7 post-infection, the cellsin each well were resuspended and a 100 μl sample of each cellsuspension was removed for assay. A 20 μl volume of a 5 mg/ml solutionof 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)was added to each 100 μl cell suspension, and the cells were incubatedfor 4 hours at 37° C. in a 5% CO₂ environment. During this incubation,MTT is metabolically reduced by living cells resulting in the productionin the cell of a colored formazan product. To each sample was added 100μl of 10% sodium dodecylsulfate in 0.01 N HCl to lyse the cells andsamples were incubated overnight. The absorbance of each sample wasdetermined.at 590 nm using a Molecular Devices microplate reader. The %reduction of the virus induced cytopathic effect (CPE) by the testcompounds was determined using the formula shown at the bottom of Table2, hereinafter.

The results of the antiviral testing are set forth in Table 2, aspercent reduction in cytopathic effect (CPE). The inhibitory dose thatinhibits 50% of the cytopathic effect is shown as ID₅₀ (μg/ml).

                  TABLE 2                                                         ______________________________________                                        Antiviral Evaluation of Myristate Analogs                                     Percent Reduction of CPE.sup.a                                                              Concentration μ                                              Compound        100    10      1    ID.sub.50 (μg/ml)                      ______________________________________                                        13-Oxamyristate T      43.5.sup.c                                                                            66.4 0.3 Positive                                                                  control                                   Decanoic acid   T      11.3    7.7  -- Negative                               (C.sub.10).sup.b                    control                                   12-Azidododecanoic                                                                            T      38.2.sup.c                                                                            81.7 0.3                                       acid (1)                                                                      11-Azidoundecanoic                                                                            T      34.6.sup.c                                                                            16.3 --                                        acid (2)                                                                      12-Azido-9-oxa-DDA (41)                                                                       --     66      14   5                                         12-Azido-3-oxa-DDA (43)                                                                       --     --      --   Inactive                                  12-Azido-6-oxa-DDA (42)                                                                       --     20      4    Inactive                                  12-azido-3-thia-DDA (19)                                                                      T      54      1    9.2                                       12-azido-4-thia-DDA (23)                                                                      T      0       0    Inactive                                  12-azido-6-thia-DDA (13)                                                                      T      14      0    Inactive                                  12-tetrazoyl-DDA (46)                                                                         --     65      12   5.9                                       12-(1,2,4-triazoyl)-DDA (48)                                                                  T      66      24   4.2                                       12-(1,2,3-triazoyl)-DDA (50)                                                                  T      30.8    19.5 --                                        ______________________________________                                         DDA = Dodecanoic Acid                                                    

    __________________________________________________________________________    Compound                                                                            0.5 μ/ml                                                                         0.1 μg/ml                                                                        0.01 μg/ml                                                                       0.001 μg/ml                                                                       ID.sub.50 (μg/ml)                           __________________________________________________________________________    AZT   87.8  100.8 84.8  58.2   <0.001                                         __________________________________________________________________________     .sup.a The percent reduction of viral CPE was calculated by the formula:      ##STR4##                                                                      .sup.b Solubitlity problem; precipitate at highest test concentration.        .sup.c Value may be arificially low because of partial toxicity at this       test concentration.                                                      

The biologically active fatty acid analogs described herein can be usedfor administration to a mammalian host or host cells infected withretroviruses such as HIV and the like by conventional means, preferablyin formulations with pharmaceutically acceptable diluents and carriers.The amount of the active agent to be administered must be an effectiveamount, that is, an amount which is medically beneficial but does notpresent toxic effects which overweigh the advantages which accompany itsuse. It would be expected that the adult human dosage would normallyrange upward from about one milligram of the active compound. A suitableroute of administration is orally in the form of capsules, tablets,syrups, elixirs and the like, although parenteral administration alsocan be used. Appropriate formulations of the active compound inpharmaceutically acceptable diluents and carriers in therapeutic dosageform can be prepared by reference to general texts in the field such as,for example, Remington's pharmaceutical sciences, Ed. Arthur Osol, 16thed., 1980, Mack Publishing Co., Easton, Pa.

Various other examples will be apparent to the person skilled in the artafter reading the present disclosure without departing from the spiritand scope of the invention. All such other examples are included withinthe scope of the appended claims.

What is claimed is:
 1. A composition of matter having a chemicalstructure as follows:

    Z--(CH.sub.2).sub.x COOR

wherein Z=azido, tetrazolyl or triazolyl, R=H or C₁ -C₈ alkyl,X=7-11,wherein an oxygen or sulfur is positioned between said two CH₂groups from carbon position 2 to within 1 carbon or Z and wherein saidtetrazolyl and said triazolyl are attached to said (CH₂)_(x) COOR at aprimary nitrogen and wherein said tetrazolyl is a mixture of N-1 and N-3isomers and said triazolyl is an N-1 isomer.
 2. The compound of claim 1in which Z is azido, R is H and a methylene group is replaced withoxygen.
 3. The compound of claim 2 in which x is 6 and in which themethylene group in carbon position 6 is replaced with oxygen.
 4. Thecompound of claim 2 in which x is 3 and in which the methylene group incarbon position 9 is replaced with oxygen.
 5. The compound of claim 1 inwhich Z is azido, R is H and a methylene group is replaced with sulfur.6. The compound of claim 5 in which x is 6 and in which the methylenegroup in carbon position 6 is replaced with sulfur.
 7. A method ofinhibiting virus in vitro in host cells infected with said viruscomprising treating said host cells with a virally inhibitory effectiveamount of a fatty acid analog composition of matter of the followingchemical structure:

    Z--(CH.sub.2).sub.x COOR

wherein Z=azido, tetrazolyl or triazolyl, R=H or C₁ -C₈ aklyl, X=8-12andwherein said tetrazolyl and said triazolyl are attached to said(CH₂)_(x) COOR at a primary nitrogen and wherein said tetrazolyl is amixture of N-1 and N-3 isomers and said triazolyl is an N-1 isomer. 8.The method of claim 7 in which a methylene group from carbon position 3to within 2 carbons of Z is replaced by oxygen or sulfur.
 9. The methodof claim 7 is which the virus is HIV.
 10. The method of claim 9 in whichthe fatty acid analog is 12-azidododecanoic acid.
 11. The method ofinhibiting HIV virus in vitro in host cells infected with said viruscomprising treating said host cells with a virally inhibitory effectiveamount f 2-(1-azido-nonane-9-thia)-acetic acid.
 12. The method ofinhibiting HIV virus in vitro in host cells infected with said viruscomprising treating said host cells with a virally inhibitory effectiveamount of 8-(1-azido-propane-3-oxa)-octanoic acid.
 13. The method ofclaim 9 in which the fatty acid analog is 12-(tetrazolyl)-dodecanoicacid.
 14. The method of claim 9 in which the fatty acid analog is12-([1,2,4-]-triazolyl)-dodecanoic acid.
 15. The method of claim 9 inwhich the fatty acid analog is 12-([1,2,3]-triazolyl)-dodecanoic acid.